NCT04084717 - Study of Crizotinib for ROS1 and MET Activated Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 3, 2019

Primary Completion Date

December 31, 2024

Study Completion Date

June 30, 2025

Conditions

Non-squamous Non-small-cell Lung CancerStage IV Non-small Cell Lung CancerROS1 Gene RearrangementMET Activating MutationMET Amplification

Interventions

DRUG

Crizotinib

"Crizotinib is an orally administered, chemotherapy drug that works by blocking ALK, MET and ROS1 receptor tyrosine kinases from working.~Participants will receive crizotinib, orally (by mouth), at a dose of 250 mg, twice per day, every day of each 28 day cycle."

Trial Locations (1)

M5G 1Z5

RECRUITING

Princess Margaret Cancer Centre, Toronto